Unless
otherwise defined herein, the capitalised terms used in this
announcement have the same meaning as those used in the Company's
announcements released on 13 February 2025.
17 February 2025
Physiomics plc
("Physiomics" or the "Company")
Result of WRAP Retail
Offer
Physiomics plc (AIM: PYC), is pleased to
announce, further to the announcements made on 13 February 2025,
the completion of the WRAP Retail Offer, at the same price as the
previously announced Placing (together the "Fundraise"). The WRAP Retail
Offer, which closed at 11 a.m. today, has raised aggregate gross
proceeds of £70,000 through the issue of a total of 14,000,000 new
Ordinary Shares, alongside the previously announced Placing of
£430,000. The WRAP Retail Offer was slightly oversubscribed and was
therefore subject to a small scale back.
The Fundraise, which is conditional on
Admission, raised gross proceeds of, in aggregate, £500,000, via
the issue of 86,000,000 Placing Shares pursuant to the Placing and
14,000,000 WRAP Retail Offer Shares pursuant to the WRAP Retail
Offer.
Use of
Proceeds
In order to further develop its business and
accelerate growth, the Company is raising funds to carry out the
following activities and for general working capital:
·
Mathematical Modelling Consulting Service
o Recruitment of
further technical team members to accelerate the conversion of the
pipeline and support service delivery;
o Investment in
Business Development and Marketing to build and strengthen the
pipeline, expand into new therapeutic areas, further develop its
data science offering and refresh messaging; and
o Explore
strategic options to accelerate the growth of modelling
services.
·
Biostatistics Consulting Service
o Organic growth
of the service though Business Development and Marketing to acquire
clients; and
o Explore
strategic options to accelerate the growth of biostatistics
services.
·
Personalised Medicine Tool Development
o Explore a
deeper relationship with DoseMe to develop models to be implemented
on their platform; and
o Implementation
of the Company's current personalised dosing tool on the DoseMeRx
Platform enabling it to be made available to clinicians across the
US.
Admission and
Total Voting Rights
Applications have been made for the Placing
Shares and the WRAP Retail Offer Shares to be admitted to trading
on AIM, which is expected to become effective and dealings commence
on or around 8.00 a.m. on 18 February 2025 ("Admission").
Following Admission, the Company's issued
ordinary share capital will consist of 303,208,718 Ordinary Shares.
Since the Company currently holds no Ordinary Shares in treasury,
the total voting rights in the Company will be 303,208,718. These
figures may be used by shareholders of the Company as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the Company under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules.
The new Ordinary Shares to be issued pursuant
to the WRAP Retail Offer will be issued free of all liens, charges
and encumbrances and will, on Admission, rank pari passu in all respects with the
new Ordinary Shares to be issued pursuant to the Placing and the
Company's existing Ordinary Shares.
For further
information, please contact:
|
Physiomics
plc
|
+44 (0) 1235
841575
|
|
Dr Peter Sargent, CEO
|
|
|
|
|
Hybridan LLP
(Broker)
|
+44 (0) 203 764
2341
|
|
Claire Louise Noyce
|
|
|
|
|
|
Strand Hanson
Limited (NOMAD)
James Dance & James Bellman
|
+44 (0) 20 7409
3494
|
|
Winterflood
Retail Access Platform
|
WRAP@winterflood.com
|
|
Joe Winkley, Sophia Bechev
|
+44 (0)20 8100
0000
|
Further information on the Company can be found
on its website at www.physiomics.co.uk
The Company's LEI is
213800A71DSZ6ABMTQ91.
